Tripotassium dicitratobismuthate 120mg tablets
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Tripotassium dicitratobismuthate
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
WHO defined daily dose (DDD)
480 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 15 studies.
1990–2025
Showing all 15 studies, sorted by most relevant.
Himani Singh, Qammer Majid, Richu, et al.
Journal of Chemical & Engineering Data, 2023
S. Dill, J. Payne-James, J. Misiewicz, et al.
Gut, 1990
- Antacids
- Bacteriological Techniques
- Bismuth
Shunjun Wang, Huayang Li, Quan Liu, et al.
International heart journal, 2024
- Citrates
- Hypertension, Pulmonary
- Hypoxia
Sanghun Yun, A. J. Chabert, Holger Militz
Materials, 2024
Wood modification has been explored in various ways to enhance dimensional stability and reduce flammability, with a focus on environmentally friendly treatments to meet market demands. This study aimed to investigate the efficacy of new, potential fire-retardant materials. Specifically, the study examined the combination of tripotassium citrate (TPC), a water-soluble and bio-based fire retardant, with sorbitol and citric acid (SorCA), an eco-friendly thermosetting resin previously studied. While TPC is known to control combustion, its application in wood modification has not been thoroughly researched. To assess the fixation and flammability of these fire retardants, tests were conducted on Scots Pine (Pinus sylvestris L.), including chemical analysis, dimensional stability, mechanical properties, flame retardancy, and leaching tests. The combination of SorCA and TPC showed high weight percent gain (WPG) values; however, leaching and anti-swelling efficiency (ASE) tests revealed challenges in fixation stability. The dynamic mechanical properties were reduced, whereas the static strength values were in the same range compared with untreated wood. While TPC exhibited high flame retardancy prior to leaching, its efficacy diminished post-leaching, underscoring challenges in fixation and the need for improved retention strategies. Bunsen burner tests conducted on leached specimens indicated enhanced performance even under severe leaching conditions as per the EN 84:2020 procedure. However, cone calorimetry measurements showed less favorable outcomes, emphasizing the necessity for further investigation into optimizing TPC retention and enhancing treatment efficacy.
Abstract licence: CC BY
D. Wardana, F. Firmansyah, Widayana Tri Meiliya, et al.
Journal of Student Research, 2023
Reactions Weekly, 2024
Reactions Weekly, 2025
Reactions Weekly, 2024
D. Kurniasih, M. Ashari, Aditya Maharani, et al.
Metta : Jurnal Ilmu Multidisiplin, 2025
Based on data from the Indonesian Police and Fire Department, the number of fire incidents is quite high and the most frequent fires are residential buildings. Therefore, it is necessary to conduct research related to materials that can inhibit the spread of fire. This research was conducted with the intention of determining the ability of Tripotassium Citrate in sweet potato skin and Citric Acid in inhibiting the spread of fire. The purpose of this study was to determine which material is more effective by testing and combining the dosage of each material. The method used was to conduct an experimental test on the combination of these materials in inhibiting the spread of fire. The aspects measured in this study were the mass loss and the area burned from each sample. The experimental results show that Tripotassium citrate has a function in slowing down the fire ignition stage with a mass loss ranging from 0.67 - 0.97 grams and a percentage of burned area ranging from 17.54% - 23.85%. While citric acid has a function in slowing down the fire growth stage with a mass loss ranging from 0.01 - 0.17 grams and a percentage of burned area ranging from 1.75% - 7.08%. The combination of the two materials produced results with a mass loss ranging from 0.2 - 0.8 grams and a percentage of burned area ranging from 4.27% - 14.04%. With these results, it can be concluded that Tripotassium Citrate and Citric Acid can be used as fire retardants.
Abstract licence: CC BY-SA
Supri Hartini, I. Gede, Andika Sukarya, et al.
Global Medical & Health Communication (GMHC), 2025
Hematological examination is essential for clinical diagnostics. The accuracy of hemoglobin measurements depends on the proper handling of pre-analytical samples. Storage of tripotassium ethylene diamine tetraacetic acid (K3EDTA) blood samples for too long at room temperature can lead to erythrocyte changes that affect test results. This study aims to determine the effect of K3EDTA blood sample storage time at 1 hour, 6 hours, and 24 hours at room temperature on hemoglobin levels. This comparative analysis study was carried out at the Hematology Laboratory, Diploma III Medical Laboratory Technology Program, Health Polytechnic Ministry of Health of East Kalimantan, on November 4–5, 2024. The study used 42 venous blood samples collected in K3EDTA tubes from 25 men and 17 women aged 18–55 years. Hemoglobin levels were measured using the cyanmethemoglobin method at three time points: 1, 6, and 24 hours at room temperature (20–25°C). Statistical analysis used one-way analysis of variance (ANOVA), followed by the post hoc Tukey's honestly significant difference (HSD) test. The mean hemoglobin values at 1, 6, and 24 hours were 14.8, 15.2, and 14.9 g/dl (male) and 13.3, 14.3, and 13.3 g/dl (female), respectively. ANOVA showed significant differences (p=0.001). Post hoc analysis revealed substantial differences between 1-hour and 6-hour storage (p=0.001) and between 6-hour and 24-hour storage (p=0.003), but not between 1-hour and 24-hour storage (p=0.766). In conclusion, storage time has a significant effect on hemoglobin measurements, with critical changes occurring at 6 hours, providing evidence-based guidance for pre-analytical quality assurance.
Abstract licence: CC BY-NC-SA
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q48838266), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.